Comparison of allopurinol and probenecid.
作者信息
Scott J T
出版信息
Ann Rheum Dis. 1966 Nov;25(6 Suppl):623-6. doi: 10.1136/ard.25.Suppl_6.623.
Abstract
摘要
相似文献
1
Comparison of allopurinol and probenecid.别嘌醇与丙磺舒的比较。
Ann Rheum Dis. 1966 Nov;25(6 Suppl):623-6. doi: 10.1136/ard.25.Suppl_6.623.
2
Allopurinol (xanthine oxidase inhibitor) in the treatment of resistant gout.别嘌醇（黄嘌呤氧化酶抑制剂）用于治疗难治性痛风。
JAMA. 1966 Nov 14;198(7):708-12.
3
Treatment of gout.痛风的治疗。
N Engl J Med. 1971 Dec 2;285(23):1303-6. doi: 10.1056/NEJM197112022852306.
4
Drug treatment of gout.痛风的药物治疗
Semin Drug Treat. 1971 Sep;1(2):119-47.
5
Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone.别嘌醇与磺吡酮联合及单独使用别嘌醇治疗痛风。
Ann Rheum Dis. 1966 Nov;25(6 Suppl):634-42. doi: 10.1136/ard.25.Suppl_6.634.
6
Allopurinol in primary gout with and after the administration of uricosuric agents.原发性痛风中及给予促尿酸排泄药物后使用别嘌醇的情况。
Ann Rheum Dis. 1966 Nov;25(6 Suppl):643-4. doi: 10.1136/ard.25.Suppl_6.643.
7
Hyperuricemia and gout.高尿酸血症与痛风。
West J Med. 1985 Jan;142(1):104-7.
8
Zyloprim and other drugs in the management of gout.别嘌醇及其他药物在痛风治疗中的应用
Med Lett Drugs Ther. 1966 Dec 2;8(24):98-9.
9
Current therapy of gout and hyperuricemia.
Hosp Pract. 1976 May;11(5):69-76. doi: 10.1080/21548331.1976.11706934.
10
Drug control of gout and hyperuricaemia.痛风和高尿酸血症的药物治疗
Drugs. 1978 Aug;16(2):158-66. doi: 10.2165/00003495-197816020-00005.
引用本文的文献
1
The Treatment of Gout-1967.痛风的治疗——1967年
J R Coll Physicians Lond. 1967 Jul;1(4):427-441.
2
An old disease with new insights: Update on diagnosis and treatment of gout.一种有新见解的古老疾病：痛风诊断与治疗的最新进展
Eur J Rheumatol. 2014 Jun;1(2):72-77. doi: 10.5152/eurjrheumatol.2014.021. Epub 2014 Jun 1.
3
Uricosuric medications for chronic gout.用于慢性痛风的促尿酸排泄药物。
Cochrane Database Syst Rev. 2014 Nov 14;2014(11):CD010457. doi: 10.1002/14651858.CD010457.pub2.
4
Allopurinol for chronic gout.用于慢性痛风的别嘌醇。
Cochrane Database Syst Rev. 2014 Oct 14;2014(10):CD006077. doi: 10.1002/14651858.CD006077.pub3.
5
Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.泰国人群中HLA - B*5801检测在预防别嘌醇诱导的重症多形红斑/中毒性表皮坏死松解症中的成本效益分析。
PLoS One. 2014 Apr 14;9(4):e94294. doi: 10.1371/journal.pone.0094294. eCollection 2014.
6
Optimizing current treatment of gout.优化痛风的当前治疗。
Nat Rev Rheumatol. 2014 May;10(5):271-83. doi: 10.1038/nrrheum.2014.32. Epub 2014 Mar 11.
7
Pain management in gout.
Curr Pain Headache Rep. 2008 Dec;12(6):418-22. doi: 10.1007/s11916-008-0071-9.
8
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?苯溴马隆治疗痛风的获益-风险评估。其退市符合患者的最大利益吗？
Drug Saf. 2008;31(8):643-65. doi: 10.2165/00002018-200831080-00002.
9
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).欧洲抗风湿病联盟关于痛风的循证推荐意见。第二部分：管理。欧洲抗风湿病联盟国际临床研究包括治疗学常务委员会（ESCISIT）特别工作组报告
Ann Rheum Dis. 2006 Oct;65(10):1312-24. doi: 10.1136/ard.2006.055269. Epub 2006 May 17.
10
Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?痛风治疗：循证依据是什么，我们如何确定并推广优化的临床护理？
Curr Rheumatol Rep. 2005 Jun;7(3):242-9. doi: 10.1007/s11926-996-0046-y.
Zotero 插件